Legionella Testing Market Size, Share, & Trends Analysis Report By Type (Water Testing, IVD Testing), By End-use (Microbial culture, Direct Fluorescent Antibody (DFA) Stain, PCR, Others), By Region,- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2025-2034

Legionella Testing Market Size and Research

The legionella testing market size was exhibited at USD 305.84 million in 2024 and is projected to hit around USD 678.86 million by 2034, growing at a CAGR of 8.3% during the forecast period 2025 to 2034.

Legionella Testing Market Size 2024 To 2034

Legionella Testing Market Key Takeaways:

  • The water testing segment held the largest revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period.
  • The microbial culture segment accounted for the largest revenue share of 38.0% in 2024.
  • The PCR segment is expected to grow at the fastest CAGR of 8.8% during the forecast period.
  • Europe dominated the market and accounted for the largest revenue share of 40.0% in 2024.
  • Asia Pacific is expected to grow at the fastest CAGR of 9.6% during the forecast period.

Report Scope of Legionella Testing Market

Report Coverage Details
Market Size in 2025 USD 331.22 Million
Market Size by 2034 USD 678.86 Million
Growth Rate From 2025 to 2034 CAGR of 8.3%
Base Year 2024
Forecast Period 2025-2034
Segments Covered Type, End-use, Region
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Regional scope North America; Europe; Asia Pacific; Latin America; MEA
Key Companies Profiled Abbott; Beckman Coulter, Inc.; BD; Bio-Rad Laboratories, Inc.; BIOMÉRIEUX; Eiken Chemical Co., Ltd.; Hologic, Inc.; Pro Lab Diagnostics Inc.; QIAGEN; F. Hoffmann-La Roche Ltd.; Takara Bio Inc.; Thermo Fisher Scientific Inc.

The increasing incidence of Legionella-related disorders and rising awareness about their preventive management is expected to drive market growth. Legionella can cause Legionellosis, a respiratory disorder (a form of pneumonia). It requires intensive care and hospitalization; hence, it is considered one of the public health concerns. According to the Centers for Disease Control and Prevention, approximately 10,000 cases of Legionnaires’ disease were reported in 2034.

As Legionella bacteria grow in hot water conditions, various industries that rely on water storage are prone to developing Legionella in water. These waterborne bacteria can harm schools, restaurants, hospitals, and large plumbing systems. Therefore, industries increasingly demand accurate and on-time diagnosis of Legionella and related infections.In September 2024, four deaths and 11 instances of severe pneumonia were reported in San Miguel de Tucumán, Argentina. Later, the epidemic of severe pneumonia was linked to Legionella, particularly the bacterium L. pneumophila. In addition, in June 2024, the New York Attorney General signed an agreement with Verizon to ensure the company takes prompt and thorough action to stop the Legionnaires' disease from spreading throughout New York State.

Legionella Testing Market By Type Insights

On the basis of type, the market is segmented into water testing and IVD testing. The water testing segment held the largest revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period. The factors contributing to the segment growth mainly include government laws that mandate the testing for Legionella. For instance, in many European countries, Legionella testing is mandatory by law and must be conducted.

Time constraint is the most important drawback of conventional testing methods, as it can take weeks to deliver the results and fail to provide accurate results on time. The absence of accurate diagnostics can lead to presumptive treatment or delay it. It can further hamper the treatment measures and cause outbreaks. Therefore, there is a need for the development of new and advanced diagnostics tools.

The conventional testing methods are labor-intensive and involve manual interference, which can cause contamination and affect the outputs. The diagnostic technological advancements in terms of automation and digitization are responsible for market growth.

Automation facilitates up to 50% timesaving in diagnostic procedures, as it reduces the burden of manual efforts. In addition, results are reliable, precise, and sensitive. Diagnostic lab automation generates standardized and reproducible results. Therefore, advanced rapid diagnostic methods are gaining popularity, and their demand will continue to expand in the coming years. However, a limited number of manufacturing companies can challenge market growth.

Legionella Testing Market By End-use Insights

Based on end use, the market is segmented into microbial culture, direct fluorescent antibody (DFA) stain, PCR, and others. The microbial culture segment accounted for the largest revenue share of 38.0% in 2024. Microbial culture offers high specificity and sensitivity, accurately identifying Legionella bacteria. Regulatory guidelines often recommend or require its use, ensuring water safety in various settings.

Pie Graph 0

The PCR segment is expected to grow at the fastest CAGR of 8.8% during the forecast period. PCR provides benefits such as timely and accurate diagnosis along with reproducible results. Hence, it is preferred as a bacterial testing method. PCR offers rapid results, often within hours, compared to the days required by microbial culture. It can detect non-viable and VBNC Legionella cells, enhancing accuracy.

Legionella Testing Market By Regional Insights

Europe dominated the market and accounted for the largest revenue share of 40.0% in 2024. The governments in some countries, such as the UK and Germany, have made Legionella testing compulsory. This is primarily due to the high levels of awareness regarding Legionellosis and related diseases. In European countries, Europe’s well-established healthcare system prioritizes water safety and disease prevention, boosting market growth.

Legionella Testing Market Share, By Regional 2024 (%)

Asia Pacific is expected to grow at the fastest CAGR of 9.6% during the forecast period. The rising geriatric population in this region, which is more prone to infections, increasing disposable income, and increasing penetration of Legionella testing products via a global distribution network, are expected to drive market growth over the forecast period. According to the World Health Organization (WHO), roughly 10 to 15 instances per million people in Europe, Australia, and the U.S. are reported for Legionellosis each year. In addition, 60-70% of reported cases are male, and 75-80% are above 50.

Some of the prominent players in the legionella testing market include:

  • Abbott
  • Beckman Coulter, Inc.
  • BD
  • Bio-Rad Laboratories, Inc.
  • BIOMÉRIEUX
  • Eiken Chemical Co., Ltd.
  • Hologic, Inc.
  • Pro Lab Diagnostics Inc.
  • QIAGEN
  • F. Hoffmann-La Roche Ltd.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the legionella testing market

By Type

  • Water Testing
  • IVD Testing

By End-use

  • Microbial Culture
  • Direct Fluorescent Antibody (DFA) Stain
  • PCR
  • Others (Serotyping)

By Regional

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Frequently Asked Questions

Some key players operating in the legionella testing market include Beckman Coulter, Inc.; Bio-Rad Laboratories, Inc.; Alere, Inc.; Roche Diagnostics; Thermo Fischer Scientific, Inc.; and Becton, Dickinson and Company (BD).

Key factors that are driving the market growth include increasing incidence of Legionella-related disorders and rising awareness about their preventive management.

The legionella testing market size was exhibited at USD 305.84 million in 2024 and is projected to hit around USD 678.86 million by 2034, growing at a CAGR of 8.3% during the forecast period 2025 to 2034.

.Europe dominated the legionella testing market with a share of 39.0% in 2024. This is attributable to the governments of countries such as the UK and Germany, that have made Legionella testing compulsory.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope

1.1.1. Type

1.1.2. End use

1.1.3. Regional scope

1.1.4. Estimates and forecast timeline

1.2. Research Methodology

1.3. Information Procurement

1.3.1. Purchased database

1.3.2. internal database

1.3.3. Secondary sources

1.3.4. Primary research

1.3.5. Details of primary research

1.4. Information or Data Analysis

1.5. Market Formulation & Validation

1.6. Model Details

1.7. List of Secondary Sources

1.8. List of Primary Sources

1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Segment Outlook

2.2.1. Type outlook

2.2.2. End use outlook

2.2.3. Regional outlook

2.3. Competitive Insights

Chapter 3. Legionella Testing Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.1.1. Parent market outlook

3.1.2. Related/ancillary market outlook

3.2. Penetration & Growth Prospect Mapping

3.3. Market Dynamics

3.3.1. Market driver analysis

3.3.2. Market restraint analysis

3.4. Legionella Testing Market Analysis Tools

3.4.1. Industry Analysis - Porter’s

3.4.1.1. Supplier power

3.4.1.2. Buyer power

3.4.1.3. Substitution threat

3.4.1.4. Threat of new entrant

3.4.1.5. Competitive rivalry

3.4.2. PESTEL Analysis

3.4.2.1. Political landscape

3.4.2.2. Technological landscape

3.4.2.3. Economic landscape

Chapter 4. Legionella Testing: Type Estimates & Trend Analysis

4.1. Legionella Testing Market: Key Takeaways

4.2. Legionella Testing Market: Movement & Market Share Analysis, 2022 & 2030

4.3. Water Testing

4.3.1. Water testing market estimates and forecasts, 2018 to 2030 (USD Million)

4.4. IVD Testing

4.4.1. IVD testing market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Legionella Testing: End Use Estimates & Trend Analysis

5.1. Legionella Testing Market: Key Takeaways

5.2. Legionella Testing Market: Movement & Market Share Analysis, 2022 & 2030

5.3. Microbial Culture

5.3.1. Microbial culture market estimates and forecasts, 2018 to 2030 (USD Million)

5.4. Direct Fluorescent Antibody (DFA) Stain

5.4.1. Direct fluorescent antibody (DFA) stain market estimates and forecasts, 2018 to 2030 (USD Million)

5.5. PCR

5.5.1. PCR market estimates and forecasts, 2018 to 2030 (USD Million)

5.6. Others (serotyping)

5.6.1. Others (serotyping) market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Legionella Testing Market: Regional Estimates & Trend Analysis

6.1. Regional Outlook

6.2. Legionella Testing Market by Region: Key Takeaways

6.3. North America

6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.3.2. U.S.

6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.3.3. Canada

6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.4. Europe

6.4.1. UK

6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.4.2. Germany

6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.4.3. France

6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.4.4. Italy

6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.4.5. Spain

6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.4.6. Denmark

6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.4.7. Sweden

6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.4.8. Norway

6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.5. Asia Pacific

6.5.1. Japan

6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.5.2. China

6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.5.3. India

6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.5.4. Australia

6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.5.5. Thailand

6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.5.6. South Korea

6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.6. Latin America

6.6.1. Brazil

6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.6.2. Mexico

6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.6.3. Argentina

6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.7. MEA

6.7.1. South Africa

6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.7.2. Saudi Arabia

6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.7.3. UAE

6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

6.7.4. Kuwait

6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis, By Key Market Participants

7.2. Market Participant Categorization

7.2.1. Abbott

7.2.1.1. Company overview

7.2.1.2. Financial performance

7.2.1.3. Product benchmarking

7.2.1.4. Strategic initiatives

7.2.2. Beckman Coulter, Inc.

7.2.2.1. Company overview

7.2.2.2. Financial performance

7.2.2.3. Product benchmarking

7.2.2.4. Strategic initiatives

7.2.3. BD

7.2.3.1. Company overview

7.2.3.2. Financial performance

7.2.3.3. Product benchmarking

7.2.3.4. Strategic initiatives

7.2.4. Bio-Rad Laboratories, Inc.

7.2.4.1. Company overview

7.2.4.2. Financial performance

7.2.4.3. Product benchmarking

7.2.4.4. Strategic initiatives

7.2.5. BIOMÉRIEUX

7.2.5.1. Company overview

7.2.5.2. Financial performance

7.2.5.3. Product benchmarking

7.2.5.4. Strategic initiatives

7.2.6. Eiken Chemical Co., Ltd.

7.2.6.1. Company overview

7.2.6.2. Financial performance

7.2.6.3. Product benchmarking

7.2.6.4. Strategic initiatives

7.2.7. Hologic, Inc.

7.2.7.1. Company overview

7.2.7.2. Financial performance

7.2.7.3. Product benchmarking

7.2.7.4. Strategic initiatives

7.2.8. Pro Lab Diagnostics Inc.

7.2.8.1. Company overview

7.2.8.2. Financial performance

7.2.8.3. Product benchmarking

7.2.8.4. Strategic initiatives

7.2.9. QIAGEN

7.2.9.1. Company overview

7.2.9.2. Financial performance

7.2.9.3. Product benchmarking

7.2.9.4. Strategic initiatives

7.2.10. F. Hoffmann-La Roche Ltd.

7.2.10.1. Company overview

7.2.10.2. Financial performance

7.2.10.3. Product benchmarking

7.2.10.4. Strategic initiatives

7.2.11. Takara Bio Inc.

7.2.11.1. Company overview

7.2.11.2. Financial performance

7.2.11.3. Product benchmarking

7.2.11.4. Strategic initiatives

7.2.12. Thermo Fisher Scientific Inc.

7.2.12.1. Company overview

7.2.12.2. Financial performance

7.2.12.3. Product benchmarking

7.2.12.4. Strategic initiatives

Proceed To Buy

USD 4500
USD 3900
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers